Neurodegenerative Disease Composition for Cognitive Decline Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for neurodegenerative diseases such as Parkinson's, Huntington's, Alzheimer's, and senile dementia are ineffective, have significant side effects, and are not well-tolerated by patients, particularly the elderly.
Innovation Solution
A composition comprising palmitoylethanolamide, an extract of Salvia miltiorrhiza with a 10% tanshinones content, and D-aspartate, optionally with inert ingredients, is used to treat and prevent cognitive deficits associated with neurodegenerative diseases, leveraging their synergistic action to improve synaptic plasticity and cognitive functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological treatments are used for neurodegenerative diseases, then some therapeutic effect may be achieved, but significant side effects occur and patient tolerance is poor
Solution Approach 1:
The patent employs a composite formulation combining three distinct active ingredients: plant sterols (from vegetable extracts), D-amino acids (such as D-aspartate or D-serine), and omega-3 fatty acids (such as DHA). This composite approach leverages the synergistic effects of each component to achieve neuroprotective, cognitive-enhancing, and therapeutic benefits while minimizing the side effects associated with single-agent pharmacological treatments for neurodegenerative diseases
2Duration of action of moving object
If conventional treatments are administered to elderly patients with neurodegenerative diseases, then disease progression may be slowed, but the treatments are not well-tolerated
Solution Approach 1:
The patent utilizes specific parameter ranges for each active ingredient to optimize both efficacy and tolerability. Plant sterols are provided at concentrations of 0.1-10% (preferably 0.5-5%), D-amino acids at 0.01-1% (preferably 0.05-0.5%), and omega-3 fatty acids at 0.1-10% (preferably 0.5-5%). These carefully controlled parameters enable sustained disease progression control while maintaining excellent patient tolerance, particularly in elderly populations
3Reliability
If pharmacological interventions are used to treat cognitive deficits, then some improvement may be achieved, but the treatments have significant side effects
Solution Approach 1:
The patent employs D-amino acids as intermediary substances that modulate NMDA receptor activity and enhance synaptic plasticity through physiological mechanisms. These intermediaries facilitate cognitive improvement by supporting neurotransmission and neuronal health without triggering the harmful side effects associated with direct pharmacological intervention on cognitive pathways
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
The present invention relates to a composition for treatment and/or prevention of neurodegenerative diseases comprising at least a vegetable extract, an amide of a fatty acid and, optionally, a natural amino acid.